BiotechTube

PI3K inhibitor BKM120 + rituximab

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

Conditions

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia

Trial Timeline

Jul 21, 2014 → Apr 9, 2019

NCT ID
NCT02049541

About PI3K inhibitor BKM120 + rituximab

PI3K inhibitor BKM120 + rituximab is a phase 1 stage product being developed by Novartis for Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue. The current trial status is completed. This product is registered under clinical trial identifier NCT02049541. Target conditions include Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma.

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02049541Phase 1Completed

Competing Products

8 competing products in Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue

See all competitors
ProductCompanyStageHype Score
Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + DexamethasoneEli LillyPhase 2
31
High dose of methotrexate + Gemcitabine + Pegaspargase + DexamethasoneEli LillyPhase 2
31
CamrelizumabJiangsu Hengrui MedicinePhase 2
31
SHR-1210Jiangsu Hengrui MedicinePhase 2
31
avelumabMerckPhase 2
31
PembrolizumabMerckPhase 2
42
carfilzomibAmgenPhase 1
29
IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)Innovent BiologicsPhase 1/2
24